Ekso Bionics Stock Price, News & Analysis

Ekso Bionics Holdings reported a record of 33 EksoNR bookings in Q3 2022, with revenues of $3.3 million, reflecting a 9.2% year-over-year increase. The nine-month revenue reached $9.4 million, a 30.6% increase from last year. Despite this growth, gross profit decreased by 6.7%, leading to a gross margin of 51%. The net loss for Q3 was $4.3 million, up from $2.0 million in the previous year. The company’s cash position stood at $29.2 million as of September 30, 2022, down from $40.4 million at the end of 2021, highlighting concerns over increasing operational costs.

Ekso Bionics Holdings (Nasdaq: EKSO) announced it will release its financial and business results for Q3 2022 on November 3, 2022, after market close. A conference call will follow at 1:30 p.m. PT to discuss these results and recent business developments. Investors can access the call by dialing 877-407-3036 (domestic) or 201-378-4919 (international), using Conference ID: 13733265. The call will be available for one month on their website.

Ekso Bionics, a leader in exoskeleton technology, announced its President and COO, Scott Davis, will present virtually at the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022. The pre-recorded presentation will be available for on-demand viewing starting at 4:00 AM PT / 7:00 AM ET on September 12, 2022, and can be accessed through the investor section of the Ekso Bionics website. Founded in 2005, Ekso Bionics develops innovative wearable robots to enhance human strength and mobility for both medical and industrial applications.

Ekso Bionics reported a strong financial performance for Q2 2022, with revenue of $3.5 million, a 57% increase year-over-year. The company secured a 510(k) FDA clearance for its EksoNR device for Multiple Sclerosis patients and booked 17 units in the quarter. Despite these positives, the net loss for common stockholders grew to $3.0 million, compared to $1.3 million in Q2 2021. The gross margin decreased to 47% due to rising costs. Cash reserves stood at $31.9 million as of June 30, 2022.

Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) announced plans to release its second quarter 2022 financial results on July 28, 2022, after market close. A conference call will follow at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results and recent business developments. Interested investors can access a live webcast via the company’s website. Ekso Bionics, established in 2005, focuses on developing exoskeleton solutions for medical and industrial applications, enhancing human capabilities through innovative wearable technology.

Ekso Bionics Holdings has received 510(k) clearance from the FDA for its EksoNR robotic exoskeleton, marking it as the first device approved for rehabilitation use in Multiple Sclerosis (MS) patients. This approval expands the exoskeleton’s application, previously cleared for stroke and spinal cord injury rehabilitation. With nearly 1 million MS patients in the U.S. and more than 2.8 million globally, EksoNR aims to enhance patient mobility and rehabilitation outcomes.

Available in over 375 centers worldwide, the device has already supported patients in taking nearly 200 million steps.

Ekso Bionics Holdings (Nasdaq: EKSO) announced the appointment of Jerome Wong as Interim Chief Financial Officer following Jack Glenn's resignation effective June 17, 2022. Wong, previously the Controller for five years, brings over 20 years of finance experience. His appointment is expected to provide a seamless transition as the company explores growth opportunities. Glenn's departure is amicable and unrelated to any company disputes. The company continues to innovate in exoskeleton technology, enhancing human capabilities in medical and industrial applications.

Ekso Bionics Holdings, listed under the symbol EKSO, will present at the H.C. Wainwright Global Investment Conference from May 23-26, 2022. The pre-recorded presentation will be available on-demand starting at 4:00 AM PT / 7:00 AM ET on May 24, 2022, and can be accessed on the investor section of the company's website.

As a leader in exoskeleton technology, Ekso Bionics focuses on enhancing human strength and mobility for both medical and industrial applications. Established in 2005, the company is headquartered in the San Francisco Bay Area.

Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) reported financial results for Q1 2022, achieving $2.6 million in revenue, up from $1.9 million in Q1 2021. The company booked 23 EksoNR units and secured its largest multi-unit order. Gross profit dropped by 2% to $1.2 million, decreasing gross margin to 47% due to increased service costs. Net loss grew to $4.6 million, or $0.36 per share, compared to a loss of $3.7 million in Q1 2021. Cash reserves were $36.2 million as of March 31, 2022, down from $40.4 million at year-end 2021.